Denmark· DK-28105519114
Opdivo
A nivolumab product containing nivolumab, registered in Denmark by Bristol-Myers Squibb Pharma EEIG. The same ATC class is registered in 13 of our 19 countries.
Checked against Danish Medicines Agency (Denmark) on
Informational only — not a medical device.
Where it is registered
Nivolumab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FF01 (nivolumab), each read from that country’s own register.
- This record: Denmark, from Danish Medicines Agency (Denmark)
- 8 of them publish a price we can compare per daily dose
Nivolumab · ATC L01FF01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Danish Medicines Agency (Denmark)- Active substance
- Nivolumab
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG
- Country
- Denmark (DK)
- ATC code
- L01FF01
- ATC class
- Nivolumab
- Defined daily dose
- 17.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- Danish Medicines Agency (Denmark)
- Last checked
- September 30, 2026
Packs & prices · 1
- dk_varenummer28105519114
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
22 interactions on record for nivolumab.
Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nivolumab · interactions on record
22 records
- 3 severe
- 19 moderate
Most severe, free to view
- ThalidomideL04AX02severe
- LenalidomideL04AX04severe
- PomalidomideL04AX06severe
- PrednisoloneA07EA01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L01FF01
Nivolumab, as other registers publish it.
- FinlandNivolumab BmsBristol-Myers Squibb Pharma EEIG
- United KingdomNivolumab BMS 100mg/10ml concentrate for solution for infusion vialsBristol-Myers Squibb Pharmaceuticals Ltd
- United KingdomNivolumab BMS 40mg/4ml concentrate for solution for infusion vialsBristol-Myers Squibb Pharmaceuticals Ltd
- IcelandOpdivoBristol-Myers Squibb Pharma EEIG*
- NorwayOpdivoBristol-Myers Squibb Pharma EEIG
- NorwayOpdivoBristol-Myers Squibb Pharma EEIG
- DenmarkOpdivoBristol-Myers Squibb Pharma EEIG
- DenmarkOpdivoBristol-Myers Squibb Pharma EEIG
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Danish Medicines Agency (Denmark). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c7235b98-2d65-427f-8f07-ad9b3e935e71 GET /v1/drugs/c7235b98-2d65-427f-8f07-ad9b3e935e71?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "koncentrat til infusionsvæske, opløsning",
"source": "dkma",
"strength": "100 mg/10 ml",
"auth_role": "MOD",
"dk_drugid": "28105519114",
"substance": "Nivolumab",
"auth_procedure": "Central",
"in_medicinpriser": true,
"registration_date_serial": "42179"
}See everything about nivolumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.